Advertisement
DXCM vs LIVN
Which Stock Would AI Choose? DexCom (DXCM) vs. LivaNova (LIVN) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: Based on observable trend consistency, margin expansion, and catalyst breadth, Tickeron's AI currently favors DXCM in this head-to-head comparison.
- DXCM (DexCom) is a large-cap continuous glucose monitoring (CGM) leader delivering beat-and-raise results with expanding margins.
- LIVN (LivaNova) is a mid-cap medical device maker trading near 52-week highs, driven by cardiopulmonary and neuromodulation growth.
- Both stocks carry favorable analyst ratings, but DXCM offers greater scale, a larger addressable market, and multiple clinical and reimbursement catalysts.
- Explore DXCM Major News and DXCM Today's Price Move, as well as LIVN Major News and LIVN Today's Price Move, for up-to-the-minute developments on each ticker.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Introduction
Investors evaluating medical device and technology names often weigh large, established franchises against smaller, faster-moving challengers. This stock comparison examines DXCM, a global leader in continuous glucose monitoring, and LIVN, a diversified maker of cardiopulmonary and neuromodulation devices. Both companies serve unmet clinical needs, operate in defensive healthcare markets, and have posted improving relative performance in recent quarters. The comparison is most relevant to growth-oriented traders and investors assessing relative performance, market positioning, and momentum between two profitable, innovation-driven medtech businesses with very different market capitalizations and growth drivers.
DXCM Overview and Recent Performance
DXCM is DexCom, Inc., a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes and metabolic health. Recent market activity has been constructive, with the stock gaining roughly 25% year-to-date and outperforming its broader industry. In its most recent quarter, DexCom reported revenue of $1.34 billion, up about 11% year over year, alongside adjusted earnings per share (EPS) that beat consensus estimates. U.S. revenue growth accelerated to roughly 14%, while international growth moderated to about 5% due to tougher reimbursement comparisons.
Sentiment has been supported by expanding margins—gross margin approached 65% and operating margin exceeded 25%—as well as the rollout of the G7 15 Day sensor, which management expects to reach nearly half of its U.S. customer base by year-end. A key catalyst is the CONNECT study, published in the New England Journal of Medicine, which showed meaningful A1C (a measure of average blood sugar) improvement in non-insulin Type 2 diabetes patients. Management also raised full-year revenue guidance and authorized an additional $1 billion share repurchase program.
LIVN Overview and Recent Performance
LIVN is LivaNova PLC, a medical technology company operating in two segments: Cardiopulmonary (heart-lung machines, oxygenators, and related equipment) and Neuromodulation (the VNS Therapy system for drug-resistant epilepsy and depression). The stock has been a strong performer, with its market capitalization rising sharply year over year and shares trading near 52-week highs. In its latest quarterly report, LivaNova posted revenue of about $393 million, up roughly 10% year over year, and raised its full-year adjusted EPS outlook.
Performance has been driven by double-digit growth in the Cardiopulmonary and epilepsy businesses, aided by a roughly 50% increase in U.S. Medicare reimbursement for VNS Therapy effective in 2026. Investor attention has also centered on the company's emerging obstructive sleep apnea (OSA) opportunity, anchored by its PolySync programming technology and the aura6000 system. Several analysts raised price targets following the recent report, reflecting an improved growth and margin trajectory.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots chosen for their suitability to current market conditions. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and sets of tickers they follow. Because markets shift continuously, only a subset of these bots is featured in the Trending AI Robots section at any given time, helping traders identify strategies aligned with prevailing conditions. Whether you are comparing stocks like DXCM and LIVN or scanning the broader market, exploring Trending AI Robots can provide a data-driven starting point for your analysis.
Head-to-Head Comparison
The two companies differ sharply in scale and focus. DXCM is a roughly $30 billion-market-cap pure play in diabetes technology, while LIVN is a roughly $5 billion-market-cap diversified device maker spanning cardiopulmonary and neuromodulation. DXCM's growth thesis centers on expanding CGM adoption beyond insulin-dependent patients, supported by clinical data and reimbursement tailwinds. LIVN's thesis leans on durable consumables demand, improved VNS reimbursement, and a longer-dated OSA pipeline.
On momentum, both have performed well, but DXCM offers greater consistency through manufacturing efficiencies and margin expansion, while LIVN carries higher cyclical sensitivity to procedure volumes and reimbursement timing. In valuation terms, LIVN trades at a lower forward earnings multiple, while DXCM commands a premium for its larger addressable market and growth runway. Risk factors include intense CGM competition for DXCM and clinical or regulatory execution for LIVN.
Tickeron AI Verdict
Weighing trend consistency, financial momentum, catalyst breadth, and market positioning, Tickeron's AI currently leans toward DXCM as the more favorable setup of the two. The case rests on DexCom's larger scale, accelerating U.S. growth, expanding margins, and a pipeline of near-term catalysts—including the CONNECT study's implications for broader Type 2 coverage and the ongoing G7 15 Day rollout. That said, LIVN presents a compelling, higher-momentum alternative with improving reimbursement economics. The AI verdict is probabilistic rather than definitive, reflecting a relative preference for DXCM based on currently observable data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXCM is a Buy and LIVN is a Buy.
DXCM saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for DXCM moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In 48 of the 62 cases the stock moved lower. This puts the odds of a downward move at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on DXCM as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on November 02, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 199 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LIVN in -4.46% downward trend, declining for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where LIVN declined for three days, in 229 of 309 cases, the price declined further within the following month. The odds of a continued downward trend are 74%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for LIVN moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 16 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 59 cases where LIVN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
LIVN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on LIVN as a result. In 57 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for LIVN just turned positive on October 09, 2026. Looking at past instances where LIVN's MACD turned positive, the stock continued to rise in 33 of 47 cases over the following month. The odds of a continued upward trend are 70%.
LIVN moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LIVN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +1.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIVN advanced for three days, in 206 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 109 of 186 cases where LIVN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LIVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.741) is normal, around the industry mean (4.142). P/E Ratio (26.084) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.899) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.954) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
DXCM | LIVN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 86 | |
SMR RATING 1..100 | 27 | 55 | |
PRICE GROWTH RATING 1..100 | 45 | 36 | |
P/E GROWTH RATING 1..100 | 53 | 79 | |
SEASONALITY SCORE 1..100 | 5 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LIVN's Valuation (75) in the Medical Specialties industry is in the same range as DXCM (83). This means that LIVN’s stock grew similarly to DXCM’s over the last 12 months.
LIVN's Profit vs Risk Rating (86) in the Medical Specialties industry is in the same range as DXCM (100). This means that LIVN’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is in the same range as LIVN (55). This means that DXCM’s stock grew similarly to LIVN’s over the last 12 months.
LIVN's Price Growth Rating (36) in the Medical Specialties industry is in the same range as DXCM (45). This means that LIVN’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's P/E Growth Rating (53) in the Medical Specialties industry is in the same range as LIVN (79). This means that DXCM’s stock grew similarly to LIVN’s over the last 12 months.
| DXCM | LIVN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | 3 days ago 59% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 71% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 66% |
| MACD ODDS (%) | 3 days ago 69% | 3 days ago 70% |
| TrendWeek ODDS (%) | 3 days ago 72% | 3 days ago 68% |
| TrendMonth ODDS (%) | 3 days ago 75% | 3 days ago 66% |
| Advances ODDS (%) | 7 days ago 67% | 11 days ago 68% |
| Declines ODDS (%) | 3 days ago 74% | 3 days ago 74% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 73% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DXCM’s FA Score shows that 1 FA rating(s) are green while LIVN’s FA Score has 0 green FA rating(s).
- DXCM’s FA Score: 1 green, 4 red.
- LIVN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DXCM’s TA Score shows that 5 TA indicator(s) are bullish while LIVN’s TA Score has 6 bullish TA indicator(s).
- DXCM’s TA Score: 5 bullish, 5 bearish.
- LIVN’s TA Score: 6 bullish, 4 bearish.
Price Growth
DXCM (@Medical/Nursing Services) experienced а -3.50% price change this week, while LIVN (@Medical/Nursing Services) price change was +13.95% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.27%. For the same industry, the average monthly price growth was -8.05%, and the average quarterly price growth was -7.48%.
Reported Earning Dates
DXCM is expected to report earnings on Feb 11, 2027.
LIVN is expected to report earnings on Feb 24, 2027.
Industries' Descriptions
@Medical/Nursing Services (-3.27% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
DXCM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To DXCM | 1D Price Change % | ||
|---|---|---|---|---|
| DXCM | 100% | -5.98% | ||
| ISRG - DXCM | 46% Loosely correlated | -3.36% | ||
| ALGN - DXCM | 44% Loosely correlated | +4.16% | ||
| LIVN - DXCM | 42% Loosely correlated | -1.26% | ||
| PODD - DXCM | 41% Loosely correlated | -6.16% | ||
| NVST - DXCM | 40% Loosely correlated | +0.84% | ||
More | ||||